Sign in
AMGN-AMGEN INC

Amgen's Share Price Rebounds with Strong Earnings and FDA Approval, Attracting Value Investors Amidst Mixed GLP-1 Drug Results

Tuesday

11 March, 2025

Amgen's impressive 16% share price rebound in 2025 is fueled by strong Q4 earnings and FDA approval for Lumakras, highlighting its financial resilience. With a solid pipeline and a commitment to dividends, can Amgen maintain its momentum amidst competitive pressures in the biopharmaceutical landscape?

article image for AMGN

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
74
Key Takeaways
  • Amgen shows strong investment potential with a 16% share recovery and impressive Q4 earnings growth.
  • The company reported a significant increase in free cash flow, reaching $10.4 billion.
  • FDA approval for Lumakras strengthens Amgen's oncology offerings and future growth prospects.
  • With a forward P/E ratio of 14.8 and a 3.14% dividend yield, Amgen appeals to value investors.
  • A 750% rise in dividends since 2011 underscores Amgen's dedication to shareholder returns.
Member Only Companies
Sign up to get access to all 1000+ companies covered by Foliko.
Membership is free — no credit card required.
Loading

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.